


- 47 -

**CLAIMS:**

1. A compound of Formula (I),



Formula (I)

wherein

**A** represents a direct bond or optionally substituted C<sub>1-5</sub>alkylene;

**R¹** represents hydrogen; optionally substituted C<sub>1-8</sub>alkyl; or (CH<sub>2</sub>)<sub>**b**</sub>-**R<sup>a</sup>**, wherein


10 **R<sup>a</sup>** represents C<sub>3-8</sub>cycloalkyl and **b** is zero or an integer from 1 to 6;

**R²** represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR<sup>3</sup>R<sup>3a</sup>, optionally substituted C<sub>1-8</sub>alkyl, optionally substituted C<sub>1-8</sub>alkoxy or halo;

15 **R³** and **R<sup>3a</sup>** are independently selected from hydrogen; optionally substituted C<sub>1-8</sub>alkyl and optionally substituted aryl;

**R⁴** is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g**, **III-h**, **III-i**, **III-j** or **III-k**;

- 48 -



wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

**R**<sup>6</sup> and **R**<sup>6a</sup>, are selected from:


- 5 (i) **R**<sup>6</sup> and **R**<sup>6a</sup> are independently selected from hydrogen and optionally substituted C<sub>1-8</sub>alkyl; or
- (ii) **R**<sup>6</sup> and **R**<sup>6a</sup> together represent carbonyl; or
- 10 (iii) **R**<sup>6</sup>—**A-N-R**<sup>7</sup> represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and **R**<sup>6a</sup> represents hydrogen and optionally substituted C<sub>1-8</sub>alkyl;

**R**<sup>7</sup> represents hydrogen or optionally substituted C<sub>1-8</sub>alkyl;

**R**<sup>8</sup> are selected from: : C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl and heterocyclyl wherein **R**<sup>8</sup> is optionally substituted with halo, hydroxy, amino, NO<sub>2</sub>, cyano, C<sub>1-4</sub>alkanoyloxy, N-C<sub>1-4</sub>alkylamino, N,N-di-C<sub>1-4</sub>alkylamino, HO-C<sub>2-4</sub>alkyl-NH-, HO-C<sub>2-4</sub>alkyl-N(C<sub>1-4</sub>alkyl)-, -S(O<sub>n</sub>)-C<sub>1-4</sub>alkyl, -N(R)S(O<sub>n</sub>)-C<sub>1-4</sub>alkyl, -S(O<sub>n</sub>)N(R)-C<sub>1-4</sub>alkyl or heterocyclyl optionally substituted by C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl or C<sub>2-4</sub>alkynyl, wherein **R** is hydrogen or C<sub>1-4</sub>alkyl;

**R**<sup>9</sup> is selected from:

- 49 -


- (i)  $R^9$  represents hydrogen, aryl, a 3- to 10 membered heterocyclic ring or optionally-substituted  $C_{1-8}$ alkyl; and
- (ii) the structure  $N(R^9R^{10})$  represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;
- $R^{10}$  meets the definition in option (ii) for  $R^9$  above or when  $R^9$  meets the definition in option (i) above  $R^{10}$  represents hydrogen or optionally substituted  $C_{1-8}$ alkyl;
- $R^{12}$  and  $R^{12a}$  are selected from:
- (i)  $R^{12}$  and  $R^{12a}$  are independently selected from hydrogen or optionally substituted  $C_{1-8}$ alkyl; or
- (ii)  $R^{12}$  and  $R^{12a}$  together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;
- $R^{13}$  and  $R^{14}$  are selected from:
- (i)  $R^{13}$  is selected from hydrogen; optionally substituted  $C_{1-8}$ alkyl; optionally substituted aryl;  $-R^d-Ar$ , where  $R^d$  represents  $C_{1-8}$ alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and  $R^{14}$  is selected from hydrogen; optionally substituted  $C_{1-8}$ alkyl and optionally substituted aryl;
- (ii) wherein  $R^4$  represents a group of formula **III-a**, **III-b** or **III-i**, then the group  $NR^{13}(-R^{14})$  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or
- (iii) wherein  $R^4$  represents structure **III-e**,  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;
- $n$  is 0 to 2;
- or a salt, pro-drug or solvate thereof.
2. A compound according to Claim 1 wherein  $R^9$  represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted  $C_{1-8}$ alkyl and  $R^{10}$  represents hydrogen or optionally substituted

- 50 -


- $C_{1-8}$ alkyl wherein the optional substituents on aryl, the heterocyclic ring and  $C_{1-6}$ alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S,  $-O-R^b$ ,  $C(O)NR^bR^c$ ,  $-NR^bR^c$ ,  $-NR^cC(O)-R^b$ ,  $-C(O)NR^bR^c$ ,  $-NR^cS(O_{0-2})R^b$ ,  $-S(O_{0-2})R^b$ , wherein  $R^b$  and  $R^c$  are as in Claim 1.
- 5
3. A compound according to Claim 2 wherein  $R^9$  is a  $C_{1-6}$ alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benzotriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetynyl, each of which is optionally substituted.
- 10
4. A compound according to Claim 1 wherein the structure  $N(R^9R^{10})$  represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.
- 15
5. A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from  $R^{15}$  wherein  $R^{15}$  is selected from optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted  $C_{1-4}$ alkyl wherein the optional substituents on aryl, a heterocyclic ring or  $C_{1-6}$ alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S,  $-O-R^b$ ,  $C(O)NR^bR^c$ ,  $-NR^bR^c$ ,  $-NR^cC(O)-R^b$ ,  $-C(O)NR^bR^c$ ,  $-NR^cS(O_{0-2})R^b$ ,  $-S(O_{0-2})R^b$ , wherein  $R^b$  and  $R^c$  are as defined in Claim 1.
- 20
- 25

- 51 -


6. A compound according to any one of the preceding claims wherein  $R^4$  is selected from a group of formula III-a, III-g, III-h, III-i, III-j or III-k:




III-a




III-g




III-h



III-i



III-j



III-k

- 5 6. A compound according to any one of the preceding claims wherein  $X$  and  $R^8$  represent either:-
- (a)  $X$  represents N and  $R^8$  represents cyano or  $-C(O)O-R^b$ ; or
- (b)  $X$  represents N and  $R^8$  represents hydrogen.
- 10 7. A compound according to any one of the preceding claims wherein  $R^2$  is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano,  $NR^eR^f$ , optionally substituted  $C_{1-8}$ alkyl, optionally substituted  $C_{1-8}$ alkoxy or halo wherein  $R^e$  and  $R^f$  are independently selected from hydrogen,  $C_{1-6}$ alkyl or aryl.

15

8. A compound according to any one of the preceding claims wherein  $R^1$  is hydrogen.

9. A compound selected from:

isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate;

20

isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate; and

- 52 -

2-[[{[(1*E*)-{(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]amino}carbonyl)oxy]-2-methylpropyl acetate

or a salt, pro-drug or solvate thereof.

5

10. A compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 9 for use as a medicament.

10

11. A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 9 and a pharmaceutically acceptable diluent or carrier.


15

12. Use of a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 9, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.

13. A process of producing a compound, or salt, pro-drug or solvate thereof, according to Claim 1, wherein the process comprises a reaction step selected from any one of steps (a) to (b):-

20


(a) Reaction of a compound of formula **XXXII** as follows



where X is a leaving group;

- 53 -

(b) Reaction of a compound of Formula XXXIV as follows



and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- 5    ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.